Genomma Lab Internacional SAB de CV Class B · BMV:LAB/B

Genomma Lab Internacional SAB de CV Class B — Investor Day (September 2015)

58 slides from Genomma Lab Internacional SAB de CV Class B's investor day presentation, Sep 29, 2015

  1. Slide 1: Genomma Lab Day

    Slide 1: Genomma Lab Day

    GENOMMA LAB DAY September 29, 2015

  2. Slide 2: Agenda

    Slide 2: Agenda

    AGENDA 1 Company’s Strategy and Core Competences 2 Changes in Corporate Structure 3 Track Record – Results in International Operations 4 Diversification 5 U.S.A. 6 Mexico 7 LATAM 8 Valuation, Core Brands and Learning from the Past 9 Guidance

  3. Slide 3: Company's Strategy and Core Competences

    Slide 3: Company's Strategy and Core Competences

    COMPANY’S STRATEGY AND CORE COMPETENCES 3

  4. Slide 4: Strategy: Core Competences

    Slide 4: Strategy: Core Competences

    STRATEGY CORE COMPETENCES BEFORE AFTER Demand Generation Demand Generation Win Online Talent Talent POS Execution Flawless POS Execution Mexico: Sell-in Genomma Lab: International: Sell-out, Sell-out, EBITDA, FCF EBITDA, FCF Brand Sustainability Growth Core Brands 4

  5. Slide 5: Changes in Corporate Structure

    Slide 5: Changes in Corporate Structure

    CHANGES IN CORPORATE STRUCTURE 5

  6. Slide 6: New Corporate Structure

    Slide 6: New Corporate Structure

    NEW CORPORATE STRUCTURE MÁXIMO JUDA C.E.O. RAMÓN OSCAR MARCO ALEJANDRO NEME SASTRE VILLALOBOS TORRES SPARVIERI BASTÓN PATIÑO Executive VP Executive VP Executive VP VP International and Institutional Relationships C.F.O. Global Sales Sales Development CLAUDIA LAURA SERGIO ALBERTO ORTEGA VETORETTI RAP

  7. Slide 7: Recent Changes in Key Management Positions

    Slide 7: Recent Changes in Key Management Positions

    RECENT CHANGES IN KEY MANAGEMENT POSITIONS NAME POSITION EXPERIENCE LAURA RAPINO Director BACHELOR IN BUSINESS ADMINISTRATION AND MBA Marketing, R&D • Experience in marketing and digital strategy, media and commercial planning, and budget administration. Project NESTOR FABIÁN development in Danone,

  8. Slide 8: Recent Changes in Key Management Positions

    Slide 8: Recent Changes in Key Management Positions

    RECENT CHANGES IN KEY MANAGEMENT POSITIONS NAME POSITION EXPERIENCE LAURA LÓPEZ Human Resources BACHELOR IN BUSINESS ADMINISTRATION AND HERNÁNDEZ MASTER IN HUMAN CAPITAL MANAGEMENT Director • +20 years of experience in human resources in companies such as Ryder Logística, Casa Saba and Despachos Con

  9. Slide 9: Rodrigo Herrera's Role

    Slide 9: Rodrigo Herrera's Role

    RODRIGO HERRERA’S ROLE MR. RODRIGO HERRERA ASPRA FOUNDER OF THE COMPANY AND CEO UNTIL JULY 23RD, 2015, IS CURRENTLY: • PRESIDENT of the Board • INCREASED his share of Genomma Lab from 25.9% to 29.9% in 1Q15 • PRESIDENT of the Operations Committee, meets quarterly • ADVISOR in Research & Development

  10. Slide 10: Track Record - Results in International Operations

    Slide 10: Track Record - Results in International Operations

    TRACK RECORD - RESULTS IN INTERNATIONAL OPERATIONS 10

  11. Slide 11: Track Record: Colombia

    Slide 11: Track Record: Colombia

    TRACK RECORD – RESULTS IN INTERNATIONAL OPERATIONS COLOMBIA NET SALES (MMD) EBITDA MARGIN Growth Growth 25.5PP 137% SALES PER EMPLOYEE (MMD) Variation # OF SKU’S -35% Growth 243% Note: Growth and variation rates are for 2015e compared to 2012. 11

  12. Slide 12: Track Record: Peru

    Slide 12: Track Record: Peru

    TRACK RECORD – RESULTS IN INTERNATIONAL OPERATIONS PERU NET SALES (MMD) EBITDA MARGIN Growth Growth 154% 30.1PP SALES PER EMPLOYEE (MMD) # OF SKU’S Variation 81 Growth $1.4 8% 203% $1.2 78 $0.8 75 75 $0.5 2012 2013 2014 2015E 2012 2013 2014 2015E Note: Growth rates are for 2015e compared to 2012. 12

  13. Slide 13: Track Record: Chile

    Slide 13: Track Record: Chile

    TRACK RECORD – RESULTS IN INTERNATIONAL OPERATIONS CHILE NET SALES (MMD) EBITDA MARGIN Growth Growth 21.9PP 535% SALES PER EMPLOYEE (MMD) # OF SKU’S Variation 6% Growth Growth 203% 339% Note: Growth rates are for 2015e compared to 2012. 13

  14. Slide 14: Track Record: U.S.A.

    Slide 14: Track Record: U.S.A.

    TRACK RECORD – RESULTS IN INTERNATIONAL OPERATIONS U.S.A. NET SALES (MMD) EBITDA MARGIN Growth Growth 88.4% 31.6PP 2013 SALES PER EMPLOYEE (MMD) # OF SKU’S Variation 7.4% Growth Variation 203% -6.4% Note: Growth rates are for 2015e compared to 2013. 14

  15. Slide 15: Diversification

    Slide 15: Diversification

    Genomma Lab‘ Internacional

  16. Slide 16: Diversification

    Slide 16: Diversification

    DIVERSIFICATION 34% 2016e 35% 2015e 53% 2014 62% 2013 Mexico International 2012 73% 2011 16

  17. Slide 17: International Presence

    Slide 17: International Presence

    INTERNATIONAL PRESENCE FASTEST U.S.A. GROWING RANKING IMS: NA RANKING ADVERTISER: #1 OTC COMPANY PRESENCE MEXICO CENTRAL RANKING IMS: #1 AMERICA IN 20 COUNTRIES RANKING ADVERTISER: #1 RANKING IMS: #1 RANKING ADVERTISER: #1 COLOMBIA ECUADOR RANKING IMS: #6 RANKING IMS: #3 RANKING RANKING ADVERTISER:

  18. Slide 18: Diversification Going Forward

    Slide 18: Diversification Going Forward

    DIVERSIFICATION GOING FORWARD % OF NET SALES 2015e U.S.A. 11.4% MEXICO 35.4% LATAM 53.2%

  19. Slide 19: Diversification vs. Other Companies

    Slide 19: Diversification vs. Other Companies

    DIVERSIFICATION VS. OTHER COMPANIES AMX WALMEX CEMEX ALSEA BIMBO LAB Mexico Other countries All companies as of 2Q15 LTM. LAB 2015e.

  20. Slide 20: Diversification vs. Other Companies

    Slide 20: Diversification vs. Other Companies

    DIVERSIFICATION VS. OTHER COMPANIES COMPANY ENTRANCE STRATEGY ENTRANCE STRATEGY TO BRAZIL TO THE US Acquisition Acquisition Acquisition Acquisition Acquisition Acquisition No presence Acquisition No presence Organically Organically

  21. Slide 21: U.S.A.

    Slide 21: U.S.A.

    Genomma Lab‘ Internacional

  22. Slide 22: Brand Sustainability

    Slide 22: Brand Sustainability

    BRAND SUSTAINABILITY COUGH/COLD CATEGORY AT COUGH / COLD WALGREENS Tukol Robitussin Vicks Cat avg TOTAL SHOPPERS 1,166,949 655,762 1,192,301 N/A % SHOPPERS 2 + REPEAT 16.9% 11.3% 8.2% 15.5% # OF SHOPPERS 2 + REPEAT 197,214 74,101 97,769 N/A TUKOL drives loyalty versus both the overall category and k

  23. Slide 23: Brand Sustainability

    Slide 23: Brand Sustainability

    BRAND SUSTAINABILITY COUGH SYRUP / LIQUID COMPETITORS – TOTAL MARKET SHAMPOO CATEGORY – TOTAL MARKET % OF BUYERS, % OF BUYERS, PRODUCT PRODUCT 2X + BUYERS 2X + BUYERS Cold / Allergy / Sinus Liquid / Powder Category 34.4 Shampoo 43.6 Tio Nacho 50.4 Tukol 52.8 Pantene Pro V 45.8 Vicks NyQuil 43.6 Tres

  24. Slide 24: Brand Sustainability

    Slide 24: Brand Sustainability

    BRAND SUSTAINABILITY SHAMPOO FACIAL CLEANSERS PRODUCT 3x + REPEAT PRODUCT 3x + REPEAT Category Average 5.5% Tio Nacho 6.8% Category Average 7.0% Pantene Pro V 6.3% Asepxia 8.5% Garnier Fructis 5.0% Neutrogena 8.4% Head & Shoulders 5.3% Olay 7.4% Dove 5.1% Biore 3.1% Organix 3.9% Ponds 7.7% Suave 3.8

  25. Slide 25: Success Cases in POS

    Slide 25: Success Cases in POS

    SUCCESS CASES IN POS Genomma Lab is rapidly becoming a relevant player in the general market (in USD) VS VS Last 52 Weeks Last 26 Weeks $4.3 MM $3.1 MM $1.7 MM $867 K 8,000 STORES 8,000 STORES 6,900 STORES 8,000 STORES VS Last 36 Weeks $1.8 MM $396 K 4,500 STORES 8,000 STORES Symphony/IRI Data: Lead

  26. Slide 26: GL Increases Walgreens Hispanic Market Share

    Slide 26: GL Increases Walgreens Hispanic Market Share

    GL INCREASES WALGREENS HISPANIC MARKET SHARE Share of Hispanic HAB AFTER GENOMMA 33% and growing Share of Hispanic HAB BEFORE GENOMMA 17% Source. Symphony IRI. Hispanic Snippet data. August 2015. *HAB: Health and Beauty. 26

  27. Slide 27: Genomma's Sales in Walgreens

    Slide 27: Genomma's Sales in Walgreens

    GENOMMA’S SALES IN WALGREENS STRONG GROWTH RATE AFTER MEDIA STARTED 5/8/13 (in USD) $683K MEDIA START 9/8/12 $91K Source: RSi., 52 Weeks Ending 5.18.13 27

  28. Slide 28: Presence in POS - Walgreens

    Slide 28: Presence in POS - Walgreens

    PRESENCE IN POS – WALGREENS 28

  29. Slide 29: Results in the U.S.A.

    Slide 29: Results in the U.S.A.

    RESULTS IN THE U.S.A. ALL FIGURES IN MILLION MXN$ NET SALES LTM EBITDA & MARGIN LTM % Growth: 181.6 1,159.2 15.7% 143% 20.0% Variation: 33.8PP 10.0% 2Q14 476.3 0.0% 2Q15 -10.0% -86.4 -18.1% -20.0% 2Q14 2Q15 EBITDA Var Margin FCF LTM CCC Variation: -196 Days 2Q14 2Q15* 2Q14 2Q15 ACCOUNTS RECEIVABLE 4

  30. Slide 30: U.S.A. - Potential for Growth

    Slide 30: U.S.A. - Potential for Growth

    U.S.A. – POTENTIAL FOR GROWTH Opportunity for Growth in POS 4,531 8,225 7,621 1,793 4,565 3,519 65.2% 65.2% 30.7% 30.7% 11.8% 12.8% 1.6% 11.8% 12.8% 8.8% 8.8% % In-Store Presence (Distribution Points) Number of POS Market Size $31,315 $13,289 $11,757 $10,834 $10,841 $3,841 $4,276 $18,026 $4,166 $4,0

  31. Slide 31: Mexico

    Slide 31: Mexico

    Genomma Lab‘ Internacional MEXICO

  32. Slide 32: Turnaround in Mexico

    Slide 32: Turnaround in Mexico

    TURNAROUND IN MEXICO • To increase efficiency and improve margins, we have made a significant reduction in headcount in the past months. • Inventories in our warehouse have also been reduced significantly to improve cash conversion cycle and free cash flow generation. HEADCOUNT INVENTORIES 1200 800.

  33. Slide 33: Turnaround in Mexico

    Slide 33: Turnaround in Mexico

    TURNAROUND IN MEXICO • In 2015, the Company has made significant efforts to reduce SGM&A expenses to increase profitability. SGM&A -4.1% -14.4% -5.5% -15.1% Excludimg Non-recurrent Expenses Total SGM&A

  34. Slide 34: Turnaround in Mexico

    Slide 34: Turnaround in Mexico

    TURNAROUND IN MEXICO • In the first half of 2015 we were able to significantly reduce warehouse expenses. The objective is to bring distribution expenses from ~7% of Net Sales to 2% of Net Sales. WAREHOUSE EXPENSES -64.3% Note: Monthly information. 34

  35. Slide 35: Turnaround in Mexico: Sell-out

    Slide 35: Turnaround in Mexico: Sell-out

    TURNAROUND IN MEXICO SELL-OUT • Sell-out performance improved in 2015 from 2014. Sell-out performance for 3Q15 until September 18 increased 12.7%. 1.25 1Q15 2Q15 Up-to-date 1.20 1.20 1.17 1.18 1.17 1.17 1.16 1.15 1.13 1.11 1.11 1.11 1.11 1.10 1.09 1.10 1.08 1.07 1.0687 1.07 1.06 1.06 1.06 1.05 1.05

  36. Slide 36: Results in Mexico

    Slide 36: Results in Mexico

    RESULTS IN MEXICO ALL FIGURES IN MILLION MXN$ NET SALES LTM EBITDA & MARGIN LTM % Variation: -22% 30.0% 7,202.3 25.7% 1,853.2 5,603.5 16.5% 20.0% 925.2 % Var: 10.0% EBITDA -50.1% 0.0% 2Q14 2Q15 2Q14 2Q15 EBITDA Var Margin FCF LTM CCC 2Q14 2Q15 Variation: 15 Days 2Q14 2Q15 ACCOUNTS RECEIVABLE 181 119

  37. Slide 37: Commercial Strategy - Update

    Slide 37: Commercial Strategy - Update

    COMMERCIAL STRATEGY - UPDATE POS EXECUTION 1 65% STORES in Mexico executed in line with IN-STORE VISION CHANNEL AND CUSTOMER EXPANSION 2 +58 New Customers / +27,600 Stores (Mexico and International) GO TO MARKET 3 (-)3 to 5 pts trade terms improvement and PAY FOR PERFORMANCE (Mexico and Internationa

  38. Slide 38: POS Execution

    Slide 38: POS Execution

    1 POS EXECUTION MOVE QG-5 SHELF BIO ELECTRO NEXT TEATRICAL NEXT TO ARRANGEMENT TO EXCEDRIN & PONDS WITH AT FROM NATURE TO LOMECAN AS BRAND SAME SHARE OF SHELF LEAST 20% SOS* STOMACH SEGMENT BLOCK & SYSTEM USAGE +58% +62% +21% +39% in Sales in Sales in Sales in Sales +79% L4W vs YA* +21% YTD vs YA *S

  39. Slide 39: Customer & Channel Expansion

    Slide 39: Customer & Channel Expansion

    2 CUSTOMER & CHANNEL EXPANSION # CUSTOMERS +14 New Customers +15 Customers +15 Retail /+14 Dist # STORES +1,504 /+235,000 +4,100 +22,000

  40. Slide 40: Go to Market (Pay for Performance)

    Slide 40: Go to Market (Pay for Performance)

    3 GO TO MARKET (PAY FOR PERFORMANCE) INVESTMENTS BEHIND SALES FUNDAMENTALS IMPROVEMENT: 1 2 3 4 Shelf Merchandising Distribution Pricing 3

  41. Slide 41: Commercial Innovation

    Slide 41: Commercial Innovation

    4 COMMERCIAL INNOVATION BOTIQUÍN ABARROTE: +150,000 TRADITIONAL HAIR CARE STORES (IN NEXT TWO YEARS) REINVENTION PLAN CHECK OUTS 4 +93% in Sales YTD 1,500 POS 3,000 POS 600 POS

  42. Slide 42: Marzam

    Slide 42: Marzam

    MARZAM • On August 25th, 2015 the Comisión Federal de Competencia Economica (COFECE) approved the sale of 50% plus one share of Grupo Comercial e Industrial Marzam S.A.P.I. de C.V. • According to previously negotiated contracts, the closing of the transaction took place on September 25th. In such da

  43. Slide 43: Marzam: Impact on Financial Statements

    Slide 43: Marzam: Impact on Financial Statements

    MARZAM (Impact on Genomma’s Financial Statements) ALL FIGURES IN THOUSAND MXN$ Assets June 2015(1) Movements Use of funds Proforma(2) Cash and equivalents 1,731,722 1,050,000 -950,000 1,831,722 Accounts Receivables - Net 4,683,666 350,549 5,034,215 Inventories 1,472,632 159,725 1,632,357 Assets clas

  44. Slide 44: Marzam: Proforma Financial Statements

    Slide 44: Marzam: Proforma Financial Statements

    MARZAM (Proforma Financial Statements) PROFORMA BALANCE SHEET(1) (FIGURES IN MILLION PESOS) Cash and equivalents 2,039 1,038 Suppliers 1,447 Other current liabilities A/R- Net 5,034 6,138 Secured loans and banking debt Inventories 1,632 Other current assets 1,615 639 Non current liabilities Investme

  45. Slide 45: LATAM

    Slide 45: LATAM

    Genomma Lab‘ Internacional

  46. Slide 46: New Clients

    Slide 46: New Clients

    NEW CLIENTS ARGENTINA BRAZIL COLOMBIA ECUADOR New Clients: 4 New Clients: 13 New Clients: 10 New Clients: 4 PERU DOMINICAN REPUBLIC New Clients: 2 New Clients: 2 EL SALVADOR HONDURAS GUATEMALA CHILE New Clients: 1 New Clients: 1 New Clients: 1 New Clients: 2 Bodega Farmacéutica

  47. Slide 47: Growth by Country

    Slide 47: Growth by Country

    GROWTH BY COUNTRY GROWTH BY COUNTRY 2Q15 LTM VS. 2Q14 LTM LOCAL % OF IN MXN CURRENCY LATAM SALES U.S.A. 118.0% 143.3% LATAM 25.0% 17.7% ARGENTINA 63.8% 38.9% 33.5% BRAZIL, URUGUAY AND PARAGUAY -15.0% -20.6% COLOMBIA 41.8% 33.0% ECUADOR 18.6% 31.5% BOLIVIA AND PERU 35.6% 38.3% CHILE AND CENTRAL AMERI

  48. Slide 48: Results in LATAM

    Slide 48: Results in LATAM

    RESULTS IN LATAM ALL FIGURES IN MILLION MXP NET SALES LTM EBITDA & MARGIN LTM % Var: EBITDA 30.9% 9.1% 1,483.0 31.5% 5,183.5 31.0% % Variation: 18% 30.5% 30.0% 1,359.5 29.5% 28.6% 4,403.8 29.0% % 28.5% Variation: 28.0% 2Q14 -2.3pp 2Q15 2Q14 2Q15 EBITDA Var Margin FCF LTM CCC % Variation: 798.3 139%

  49. Slide 49: Valuation, Core Brands and Learning from the Past

    Slide 49: Valuation, Core Brands and Learning from the Past

    VALUATION, CORE BRANDS AND LEARNING FROM THE PAST 49

  50. Slide 50: Valuation Hints: New Regional Disclosure

    Slide 50: Valuation Hints: New Regional Disclosure

    VALUATION HINTS: NEW REGIONAL DISCLOSURE (1) FORWARD 2016 (in million of USD*) Hint 1x Sales(2) Valuation 11x EBITDA Mexico $296 Potential 80.7% Value Upside $847 LATAM $1,226 Market Cap $1,897 14x EBITDA @17.11 p/share USA $1,050 $375 EBITDA 2016e $27 $111 SELL OUT $296 (1) Valuation multiples base

  51. Slide 51: Core Brands

    Slide 51: Core Brands

    CORE BRANDS 25 CORE BRANDS • Rational approach to brand management. Purchase, sale or licensing. • CUM Strategic business unit. Based on Company’s sell-out data, as of September 2015.

  52. Slide 52: Learning from the Past

    Slide 52: Learning from the Past

    LEARNING FROM THE PAST WHAT WE HAVE LEARNED FROM INVENTORIES MANAGEMENT 1 INCENTIVES - COMPENSATION BASED ON THE FOLLOWING METRICS: Sell-out EBITDA FCF 2 CHANGES IN POLICIES, SYSTEMS AND CONTROLS 3 COUNTRY MANAGER COMPLIANCE 52

  53. Slide 53: Guidance

    Slide 53: Guidance

    Genomma Lab‘ Internacional GUIDANCE

  54. Slide 54: Inventory Destocking at POS in Mexico

    Slide 54: Inventory Destocking at POS in Mexico

    INVENTORY DESTOCKING AT POS IN MEXICO INVENTORY DESTOCKING DISCLOSURE (In million pesos and days) $ 2,420 2,420 $ 2,127 45-60 $ 1,785 objective days of inventory $ 1,243 $ 800 $ 800 $ 800 INVENTORIES 3Q15 4Q15 1Q16 2Q16 3Q16 4Q16 4Q16 AS OF 2Q15 EXPECTED INVENTORIES 2Q15 3Q15 4Q15 1Q16 2Q16 3Q16 4Q1

  55. Slide 55: 2015 Guidance Review and 2016 Guidance

    Slide 55: 2015 Guidance Review and 2016 Guidance

    2015 GUIDANCE REVIEW AND 2016 GUIDANCE Figures in million MXN$ NET SALES 3Q15 4Q15 FY 2015 1Q16 2Q16 3Q16 4Q16 FY 2016 MEXICO 847.3 847.3 3,860.8 800.0 800.0 1,200.0 1,200.0 4,000.0 LATAM 1,429.0 1,471.2 5,811.1 1,520.8 1,477.1 1,632.9 1,649.0 6,279.8 U.S.A. 299.5 280.1 1,245.7 374.1 430.1 361.5 338

  56. Slide 56: FCF Guidance

    Slide 56: FCF Guidance

    FCF GUIDANCE (in million MXN) 50% 40% 30% 20% 8.5% 10% 5.1% 0% 2015(1) 2016 FCF As a % of sales (1) Figure not including cash flow from the sale of Marzam 56

  57. Slide 57: Final Remarks

    Slide 57: Final Remarks

    FINAL REMARKS • ONE-YEAR TURNAROUND, FINISH INVENTORY CLEANUP BY Q2 2016. • PERFORMANCE: NEW EBITDA, NET PROFIT = FCF • TRANSPARENCY AND ACCOUNTABILITY, NO EXCUSES. • MANAGEMENT’S INVESTMENTS IN GLI. • GENOMMA DAY Q3 2016. END OF OCTOBER.

  58. Slide 58: Investor Relations Contact

    Slide 58: Investor Relations Contact

    INVESTOR RELATIONS CONTACT: OSCAR VILLALOBOS – CFO ANA MARÍA YBARRA – Investor Relations inversion@genommalab.com Tel. (55) 5081-0000 ext. 5106 www.genommalab.com/inversionistas

Source: Internet Archive copy of inversionistas.genommalab.com

More decks from Genomma Lab Internacional SAB de CV Class B

All 29 Genomma Lab Internacional SAB de CV Class B decks